In women’s health, reliability is everything. Since 2014, Transo-Pharm and the German manufacturer HAPILA GmbH have joined forces to ensure a stable and high-quality supply of Estriol – an essential hormone with global relevance.
 
When demand for micronized Estriol (CEP No.: R1-CEP 2013-277-Rev 00) increased, both companies made a bold move: to invest in the future. In 2019, we decided to expand capacity at HAPILA’s site in Gera, Germany. Just one year later, construction began on a new GMP-compliant facility – now fully operational.
 
The result: a stronger, more resilient supply chain that meets today’s needs and prepares for tomorrow’s.
 
Because innovation is more than new buildings and machines – it’s about partnerships that make reliable therapies possible.
 
📹 Watch the video and see how we build the future of Estriol supply, together.

It has been three weeks now since the pharma world met in Milan for the CPHI 2024.

Three intensive days in this beautiful city were worth the efforts as they brought a lot of ideas to light, which we are now working on.
 
The whole Transo-Pharm team enjoyed meeting up with our friends and partners  – be it at a table at the Transo-Pharm booth or during our Happy Hour event with a glass of wine in our hands.
 
We are already looking forward to seeing you all again in Frankfurt in 2025.

Dear Customers,
 
On May 25th we informed you about the fire accident at our Contract Manufacturer Syn-Tech in Taiwan.
 
We are happy to inform you that the next production campaign for Epinephrine and Epinephrine bitartrate started – only 3 weeks after the incident.
 
Thanks to the Syn-Tech colleagues for this tremendeous effort and excellent support during these difficult weeks.
 
Needless to say, there are no delays in deliveries as we are still supplying the API’s from our stock in Hamburg/Germany.

Dear Customers,
 
We regret to inform you that Syn-Tech Chem. & Pharm., Co Ltd. had a fire accident on May 20, 2021. Fortunately, nobody of the employees or the firefighters were injured.
 
The production facility where Epinephrine and Epinephrine bitartrate are produced are not affected at all.
​The same applies to raw & starting material warehouse, finished product warehouse and QA/QC labs. Nevertheless, a detailed review and investigation is currently underway.
 
Due to our extensive stockpiling program at our German site, Transo-Pharm can easely compensate such an event and can continue the supply of both API’s according to the existing demands and forecasts.
 
Please be assured that we continuously keep you updated on the status at our partner in Taiwan.